Mr Serge Weinberg, board chairman and CEO, Sanofi
These new launches have the potential to cumulatively generate greater than €30 billion over the first five years of sales and confirm the strong momentum of the company's R&D pipeline and ability to deliver new therapies across a range of therapeutic categories.
"These potential launches affirm Sanofi's strategy, which has been in place since 2008, and clearly demonstrate the strong momentum of Sanofi's R&D pipeline," said Mr Serge Weinberg, chairman of the Board and CEO, Sanofi. "As we move into this period of successive new product launches, we are investing in launch excellence and execution while continuing to fuel innovation to grow our existing pipeline."
Sanofi's seminar consisted of presentations on nine new medicines and vaccines:
• Rare Diseases:
o Cerdelga (eliglustat): The only FDA-approved, first-line oral therapy for certain adult Gaucher Disease Type 1 patients.
• Multiple Sclerosis:
o Lemtrada (alemtuzumab): An FDA-approved treatment for adult patients with active relapsing remitting multiple sclerosis who have had an inadequate response to two or more MS therapies.